Documents
Application Sponsors
Marketing Status
Application Products
001 | TABLET;ORAL | 250MG | 0 | IRESSA | GEFITINIB |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2003-05-05 | PRIORITY |
LABELING; Labeling | SUPPL | 3 | AP | 2004-05-06 | PRIORITY |
LABELING; Labeling | SUPPL | 5 | AP | 2004-11-19 | PRIORITY |
LABELING; Labeling | SUPPL | 8 | AP | 2005-06-17 | PRIORITY |
Submissions Property Types
ORIG | 1 | Null | 0 |
SUPPL | 3 | Null | 0 |
SUPPL | 5 | Null | 0 |
SUPPL | 8 | Null | 0 |
CDER Filings
ASTRAZENECA
cder:Array
(
[0] => Array
(
[ApplNo] => 21399
[companyName] => ASTRAZENECA
[docInserts] => ["",""]
[products] => [{"drugName":"IRESSA","activeIngredients":"GEFITINIB","strength":"250MG","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"06\/17\/2005","submission":"SUPPL-8","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021399s008lbl.pdf\"}]","notes":""},{"actionDate":"05\/06\/2004","submission":"SUPPL-3","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/21399slr003_Iressa_lbl.pdf\"}]","notes":""},{"actionDate":"05\/05\/2003","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2003\\\/021399lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"IRESSA","submission":"GEFITINIB","actionType":"250MG","submissionClassification":"TABLET;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">No"}]
[supplements] =>
[actionDate] => 2005-06-17
)
)